Modelling therapeutic strategies in the treatment of osteoarthritis: An economic evaluation of meloxicam versus diclofenac and piroxicam

PharmacoEconomics

Volumn 21, Issue 6, 2003, Pages 443-454

  Tavakoli, Manouche ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ABDOMINAL PAIN; ADULT; AGED; ANALYSIS; ARTICLE; BLEEDING; BUDGET; CARDIOTOXICITY; CLINICAL PRACTICE; CONTROLLED STUDY; COST CONTROL; DECISION THEORY; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MODEL; NEPHROTOXICITY; NEUROTOXICITY; OSTEOARTHRITIS; PERFORATION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PUBLISHING; RASH; SAMPLE; SENSITIVITY ANALYSIS; STOMACH ULCER; TREATMENT OUTCOME; UNITED KINGDOM; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; DECISION SUPPORT TECHNIQUES; DICLOFENAC; HUMANS; MONTE CARLO METHOD; OSTEOARTHRITIS; PIROXICAM; THIAZINES; THIAZOLES;

EID: 0037263669     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321060-00007     Document Type: Article

References (39)

1. Scrip's 1999 yearbook. London: PJB Publications Ltd, 1999
2. Scheiman J. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996; 25: 279-98
3. Donnelly MT, Hawkey CJ. COX-II inhibitors: a new generation of safer NSAIDs? Aliment Pharmacol Ther 1997; 11: 227-36
4. Yuen P. OHE Compendium of health statistics. 12th ed. London: Office of Health Economics, 2000
5. Brooks P. Use and benefits of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (3A): 9S-13S
6. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105 Suppl. 1B: 31S-8S
7. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterol Endosc Clin North Am 1996; 6: 489-504
8. Laine L, Harper S, Simon T, et al. for the Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776-83
9. Fosslein E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998; 28: 67-81
10. Vane J. Towards a better aspirin. Nature 1994; 367: 215-6
11. Vane JR, Botting RM. The future of NSAID therapy: selective COX-2 inhibitors. Int J Clin Pract 2000; 54: 7-9
12. Stichtenoth DO, Wagner B, Frölich JC. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Invest Med 1997; 45: 44-9
13. Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134-43
14. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999; 96: 7563-8
15. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340 (24): 1888-97
16. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14
17. Emery P. Selective COX-2 inhibition: clinical relevance in arthritis. Curr Opin Rheumatol 1996; 8 Suppl. 1: S21-4
18. Pairet M. Selective COX-2 inhibitors: a pharmacological profile. Curr Opin Rheumatol 1996; 8 Suppl. 1: S15-9
19. Hawkey C, Kahan A, Steinbrück K, et al. for the International MELISSA Study Group. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937-45
20. Dequeker J, Hawkey C, Kahan A, et al. on behalf of the SELECT Study Group. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946-51
21. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. Oxford: Oxford University Press, 1994
22. Watson MC, Brookes ST, Kirwan JR, et al. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2001
23. Dyspepsia management guidelines. Guidelines 2000. London: British Society of Gastroenterology, 2000
24. Data on file, Boehringer Ingelheim, 1997
25. Jansen RB, Capri S, Nuitjen MJC, et al. Economic evaluation of meloxicam (7.5 mg) versus sustained release diclofenac (100 mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK. Br J Med Econ 1997; 11: 9-22
26. Tavakoli M, Prach AT, Malek M, et al. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy. Pharmacoeconomics 1999; 16: 355-65
27. MIMS: Monthly Index of Medical Specialties. November 2000. London: Haymarket Medical Ltd, 2000
28. Department of Health, National Assembly for Wales. Drug tariff: July 2000. London: Stationery Office, 2000
29. Office for National Statistics. United Kingdom National Accounts: The blue book. London: Stationery Office, 1999
30. Jansen RB, Burrell A, Nuitjen MJC, et al. An economic evaluation of meloxicam 7.5mg versus diclofenac 100mg retard in the treatment of osteoarthritis in the UK: a decision analysis model based on gastrointestinal complications. Br J Med Econ 1996; 10: 247-62
31. Chancellor JVM, Hunsche E, de Cruz E, et al. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 2001; 19 Suppl. 1: 59-75
32. Freston JW. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Am J Med 1999; 107 (6A): 78S-89S
33. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med 1999; 107 (6A): 48S-54S
34. McCarthy DM. Comparative toxicity of nonsteroidal anti-inflammatory drugs. Am J Med 1999; 107 (6A): 37S-47S
35. DIN Link data, 2000 [computer file]. Surrey: Doctors Independent Network Compufile, 2000
36. Lane NE. Pain management in osteoarthritis: Lhe role of COX-2 inhibitors. J Rheumatol 1997; 24 Suppl. 49: 20-4
37. Cannon GW, Caldwell JR, Holt P, et al. for the Rofecoxib Phase III Protocol 035 Study Group. Rofecoxib, a specific inhibitor of cyclooygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum 2000; 43: 973-87
38. Levy E, Ferme A, Perocheau D, et al. Social and economic aspects of osteoarthritis in France. Rev Rhum Ed Fr 1993; 60: 63S-7S
39. Hunsche E, Chancellor JVM, Bruce N. The burden of arthritis and nonsteroidal anti-inflammatory treatment: a European literature review. Pharmacoeconomics 2001; 19 Suppl. 1: 1-15